GlassScriptPhysician profile
Amy Martin Higgins
NPI 1013334184
$2,554.93
in general payments reported to CMS, 2019-2025
34 companies · $649 in 2025
The $649 reported for 2025 was more than what 78% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $116 · 2020: $16.31 · 2022: $80.68 · 2023: $466 · 2024: $1,227 · 2025: $649.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,331 · Education: $11.29.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,330.64 |
| Education | $11.29 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Glaxosmithkline, LLC. | $405.16 | 2019-2025 | Trelegy Ellipta, Arexvy, Bexsero |
| Abbvie INC. | $268.60 | 2023-2025 | |
| Corcept Therapeutics | $256.14 | 2024-2025 | Korlym |
| Novartis Pharmaceuticals Corporation | $195.23 | 2023-2025 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $139.98 | 2024-2025 | Ofev, Jardiance |
| Pfizer INC. | $125.35 | 2023-2025 | |
| Abbott Laboratories | $113.84 | 2023-2024 | Freestyle Libre 3 |
| Lilly USA, LLC | $109.00 | 2020-2024 | Mounjaro |
| Novo Nordisk INC | $97.41 | 2023-2025 | Ozempic, Rybelsus, Wegovy |
| Dexcom, INC. | $90.51 | 2024 | Dexcom G6 Transmitter |
| Amgen INC. | $78.42 | 2019-2024 | Evenity, Prolia, Repatha |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $77.88 | 2024-2025 | Caplyta |
| Vanda Pharmaceuticals INC. | $68.47 | 2025 | Fanapt, Hetlioz |
| Otsuka America Pharmaceutical, INC. | $62.58 | 2025 | Abilify Maintena, Rexulti |
| Janssen Pharmaceuticals, INC | $46.08 | 2025 | Spravato |
Show all 34 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Exact Sciences Corporation | $45.94 | 2023-2024 | Cologuard Collection Kit |
| Merck Sharp & Dohme LLC | $40.12 | 2019-2025 | Vaxneuvance, Capvaxive, Gardasil 9 |
| Bayer Healthcare Pharmaceuticals INC. | $34.88 | 2024 | |
| Astrazeneca Pharmaceuticals LP | $32.89 | 2023-2024 | Farxiga, Airsupra |
| Antares Pharma, INC. | $27.30 | 2024 | Xyosted |
| Takeda Pharmaceuticals U.S.A., INC. | $23.85 | 2019-2023 | Trintellix |
| Janssen Biotech, INC. | $22.00 | 2024 | Tremfya |
| Astellas Pharma US INC | $20.64 | 2024 | Veozah |
| Alkermes, INC. | $20.00 | 2025 | Lybalvi |
| Azurity Pharmaceuticals, INC. | $19.87 | 2024 | Edarbi |
| Xeris Pharmaceuticals, INC. | $17.94 | 2023 | Gvoke Hypopen |
| Supernus Pharmaceuticals, INC. | $16.29 | 2025 | Qelbree |
| Lundbeck LLC | $15.98 | 2025 | Vyepti |
| Axsome Therapeutics, INC. | $15.11 | 2025 | Auvelity |
| Melinta Therapeutics, LLC | $14.45 | 2019 | |
| Sobi, INC | $14.28 | 2019 | |
| Kowa Pharmaceuticals America, INC. | $14.00 | 2025 | Zoryve |
| Ironshore Pharmaceuticals INC. | $12.55 | 2019 | |
| Arbor Pharmaceuticals, INC. | $12.19 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Amy Higgins listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.